Abstract
In the clinical situation of cardiac arrhythmias, angina, hypertension, and myocardial infarction, beta-blockers are commonly coadministered with other pharmacologic agents, but there is still scant information available on possible pharmacokinetic interactions between betablockers and other drugs used to treat these disease states. Such interactions could be of considerable clinical importance if they lead to decreased efficacy or enhanced toxicity of other coadministered drugs. Betablockers in therapeutic doses can reduce cardiac output and hepatic blood flow and thus might reduce the total metabolic clearance rate of drugs whose systemic clearance is hepatic blood flow dependent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
